enterocin has been researched along with Leishmaniasis in 1 studies
*Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL). [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corman, HN; Fields, FR; Lee, SW; McDowell, MA; Ross, JN; Shoue, DA | 1 |
1 other study(ies) available for enterocin and Leishmaniasis
| Article | Year |
|---|---|
Rationally Designed Minimal Bioactive Domains of AS-48 Bacteriocin Homologs Possess Potent Antileishmanial Properties.
Topics: Antiprotozoal Agents; Bacteriocins; Bridged-Ring Compounds; Humans; Leishmania donovani; Leishmaniasis | 2022 |